Ennis, Stuart
Bruce, Julie
Sandhu, Harbinder
Ratna, Mariam
Lall, Ranjit
Ji, Chen
Mason, James
Kandiyali, Rebecca
Seers, Kate
Banerjee, Prithwish
Taylor, Stephanie J. C.
Robertson, Elizabeth
Underwood, Martin
McGregor, Gordon http://orcid.org/0000-0001-8963-9107
Funding for this research was provided by:
Health Technology Assessment Programme (17/129/02)
Article History
Received: 6 April 2024
Accepted: 14 July 2024
First Online: 20 July 2024
Declarations
:
: Ethical approval was received via the Integrated Research Application System (261218), the West Midlands Coventry & Warwickshire Research Ethics Committee (19/WM/0155) and the Health Research Authority on 13th July 2019. Each trial site will confirm the local NHS Trust Research & Development (R&D) department capacity and capability prior to commencing recruitment. All participants will provide written informed consent prior to participating in the trial. UHCW NHS Trust are the sponsor for the trial. The trial will be conducted in accordance with the declaration of Helsinki.
: Not applicable.
: GM and SE receive payment as directors of Atrium Health, Coventry which provides the treatment hub for the SPHERe trial.GM, MU, JB, HS, RL, CJ, JM, and KS are chief or co-investigator on multiple previous and current research grants from the UK National Institute for Health Research.MU is a co-investigator on grants funded by the Australian NHMRC and Norwegian MRC. He is a director and shareholder of Clinvivo Ltd which provides electronic data collection for health services research. He receives some salary support from University Hospitals Coventry and Warwickshire NHS Trust. He is a co-investigator on two current and one completed NIHR-funded studies that have, or have had, additional support from Stryker Ltd.JB is supported by NIHR Research Capability Funding via University Hospitals Coventry and Warwickshire NHS Trust.